Literature DB >> 21252018

Influence of age on the clinical outcomes of coronary revascularisation for the treatment of patients with multivessel de novo coronary artery lesions: sirolimus-eluting stent vs. coronary artery bypass surgery and bare metal stent, insight from the multicentre randomised Arterial Revascularisation Therapy Study Part I (ARTS-I) and Part II (ARTS-II).

Victor M Legrand1, Scot Garg, Patrick W Serruys, Kari S Virtanen, Günter Szurawitzki, Vassilis Voudris, Alessandro Fontanelli, Knut Endersen, Igor Kranjec, Tessa Rademaker, Christodoulos I Stefanidis, Kristel Wittebols.   

Abstract

AIMS: We sought to evaluate the prognostic impact of age on the procedural results and subsequent clinical outcomes in patients with multivessel disease (MVD) treated either by coronary artery bypass surgery (CABG) or by percutaneous coronary intervention (PCI) with or without drug eluting stents, based on data of the Arterial Revascularisation Therapies Study (ARTS) part I and part II. The potential influence of age in determining the most appropriate revascularisation strategy for patients with MVD is largely unknown. METHODS AND
RESULTS: Three year clinical outcome of ARTS I patients randomised to PCI with bare metal stent (BMS) (n= 600) or CABG (n= 605), and matched patients treated by PCI with sirolimus-eluting stents (SES) in ARTS II (n= 607) were reviewed according to four age quartiles. Endpoints were measured in terms of major adverse cardiac and cerebrovascular events MACCE) during hospital stay and up to three years. The frequency of female, diabetes, hypertension, peripheral vascular disease, pulmonary disease, as well as lesion complexity increased with age. At three years, MACCE free survival was comparable between patients treated by CABG or SES PCI, regardless of age quartile. The incidence of MACCE was higher among ARTS I BMS treated patients in all but the second age quartile. This was primarily related to a higher need for repeat revascularisation among BMS treated patients. However, age, which emerged as a strong independent predictor of MACCE following CABG (p<0.005), was not predictive of adverse events following PCI. Conversely, diabetes was the strongest independent predictor of MACCE among PCI treated patients (p<0.02), but didn't affect three-year outcomes following CABG.
CONCLUSIONS: Age seems to influence the CABG outcome in-hospital but not PCI. PCI-SES could offer lower immediate risk in patients with MVD and comparable long-term outcome as CABG especially in older patients. The worst outcome of PCI-BMS group is primarily related to the need for repeat revascularisation. Diabetes is the most important predictor of MACCE following PCI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252018     DOI: 10.4244/EIJV6I7A144

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  5 in total

Review 1.  Optimal revascularization for complex coronary artery disease.

Authors:  Javaid Iqbal; Patrick W Serruys; David P Taggart
Journal:  Nat Rev Cardiol       Date:  2013-09-17       Impact factor: 32.419

Review 2.  Percutaneous versus surgical interventions for coronary artery disease in those with diabetes mellitus.

Authors:  Ozlem Soran
Journal:  Curr Cardiol Rep       Date:  2013-01       Impact factor: 2.931

3.  Does Parsonnet scoring model predict mortality following adult cardiac surgery in India?

Authors:  Moningi Srilata; Narmada Padhy; Durga Padmaja; Ramachandran Gopinath
Journal:  Ann Card Anaesth       Date:  2015 Apr-Jun

4.  Changes in the Practice of Coronary Revascularization between 2006 and 2010 in the Republic of Korea.

Authors:  Yoon Jung Choi; Jin-Bae Kim; Su-Jin Cho; Jaelim Cho; Jungwoo Sohn; Seong-Kyung Cho; Kyoung Hwa Ha; Changsoo Kim
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

5.  Global Risk Score and Clinical SYNTAX Score as Predictors of Clinical Outcomes of Patients Undergoing Unprotected Left Main Percutaneous Catheter Intervention.

Authors:  Lucky Cuenza; Marianne P Collado; James Ho Khe Sui
Journal:  Cardiol Res       Date:  2017-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.